Abstract: |
Magnetic resonance imaging (MRI) has changed the landscape of breast disease diagnosis and management, and it has been incorporated into treatment algorithms according to evidence-based consensus guidelines [1–3]. In oncology, the ability to biopsy a finding seen only on MRI has been a significant advancement in the field [4–7]. Preoperatively, MRI has the ability to detect breast disease occult on other imaging modalities as well as additional sites of disease within the ipsilateral or contralateral breast, assess treatment response to neoadjuvant chemotherapy, and guide preoperative needle localization. Breast MRI also has high sensitivity for the evaluation of residual disease post-lumpectomy with positive surgical margins and the evaluation of recurrent disease [8–12]. Other more controversial and emerging uses for MRI in the preoperative setting include axillary staging and aiding in the planning of reconstructive procedures. © Springer International Publishing AG, part of Springer Nature 2013, 2019 |